NCT03949894已完成4 期
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 118
- 试验地点
- 18
- 主要终点
- The incidences of TEAEs
研究概览
简要总结
To evaluate the safety and therapeutic effectiveness of tolvaptan when administered to slow the progression of cyst development and renal function insufficiency in adult Korean patients diagnosed with rapidly progressive ADPKD who have chronic kidney disease (CKD) stages 1-3 at initiation of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who voluntarily participate by giving written informed consent on this trial
- •Male and female patients aged ≥ 19 to ≤ 50 years
- •Subjects diagnosed with ADPKD based on the Unified Criteria for Ultrasonographic diagnosis of ADPKD (Pei-Ravine Criteria)
- •Subjects with confirmed CKD stages 1-3 at the screening visit
- •Subjects with confirmed rapidly progressive typical ADPKD 'Typical ADPKD'
- •refers to bilateral and diffuse distribution, with mild, moderate or severe replacement of kidney tissue by cysts, where all cysts contribute similarly to TKV.
- •'rapidly progressive ADPKD'
- •Patients will be defined as 'rapidly progressive ADPKD' if they meet any of the following criteria:
- •Mayo class 1C, 1D or 1E
- •Truncating PKD1 mutation confirmed by genetic testing before participating this trial ③ PRO-PKD score > 6 ④ Patients with ADPKD with a decline in Estimated glomerular filtration rate(eGFR) ≥ 5 mL/min/1.73 m2 within 1 year from the screening visit or with an average annual decline in eGFR ≥ 2.5 mL/min/1.73 m2 over a period of 5 years (excluding patients with an eGFR decline due to factors other than ADPKD, such as uncontrolled type 2 diabetes, early diabetic glomerular disease or immune-mediated glomerulonephritis)
排除标准
- •Patients with hyponatremia or hypernatremia
- •Patients with anuria
- •Patients with volume depletion
- •Patients who are unable to sense or appropriately respond to thirst
- •Patients with contraindications to MRI assessment [e.g., ferromagnetic metal prosthesis, aneurysm clips, severe claustrophobia, large tattoo on the abdomen or back, etc.]
- •Patients with severe renal impairment [e.g., patients with currently active glomerulonephritis, kidney cancer, having a single kidney, history of renal surgery within the last 3 years, etc.]
- •Patients with severe hepatic impairment [e.g., cirrhosis, viral hepatitis, unspecified liver function test abnormalities (ALT or Aspartate aminotransferase(AST)) > 3 x ULN or Total Bilirubin > 2 x ULN), etc.]
- •Patients with eGFR decline due to factors other than ADPKD (e.g., uncontrolled type 2 diabetes, early diabetic glomerular disease or immune-mediated glomerulonephritis, etc.)
- •Patients with a history of hypersensitivity and/or specific reactions to benzazepine or benzazepine derivatives (such as Benazepril), or tolvaptan
- •Patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
- •Patients who need chronic diuretic use
- •Patients who are receiving any experimental (not marketed) or approved therapies that may affect the treatment of ADPKD within 6 months from the screening visit [e.g., anti-sense RNA therapy, rapamycin, sirolimus, everolimus and somatostatin analogs (octreotide, sandostatin), vasopressin antagonist (mozavaptan, conivaptan), vasopressin agonist (desmopressin)]
- •Patients who have received cyst decompression or sclerotherapy within 3 years from the screening visit
- •Patients with a history of taking tolvaptan within 6 months from the screening visit
- •Patients who received any investigational medicinal product in another trial within 30 days from the screening visit
- •Fertile women who are currently pregnant or breat feeding, or not willing to use or capable of using acceptable contraceptive methods (abstinence, oral, implanted or injected hormonal methods of contraception, intrauterine device or barrier methods of contraception, such as condom, contraceptive diaphragm and spermicidal agents) to avoid pregnancy until completion of the trial
- •Patients who are, in the opinion of the investigator, unable to comply with the administration of the Investigational Medicinal Product(IMP) or the trial procedures
研究组 & 干预措施
tolvaptan
Experimental
干预措施: Tolvaptan (Drug)
结局指标
主要结局
The incidences of TEAEs
时间窗: during the tolvaptan treatment period and up to 7 days after the date of last dosing
The incidences of TEAEs
The incidences of TEAEs meeting any of the followings will be summarized.
时间窗: during the tolvaptan treatment period and up to 7 days after the date of last dosing
Liver injury \[ALT or AST elevation (\>3 x ULN) or Total Bilirubin elevation (\>2 x ULN), etc.\], AEs leading to death, Serious AEs, AEs leading to treatment discontinuation, AEs whose causal relationship with the IMP cannot be ruled out, Severe AEs, Dehydration, Effects on Sodium, Creatinine
次要结局
- eGFR CKD-EPI annual mean change [mL/min/1.73m^2] (on-treatment)(from Completion of Tolvaptan Titration Period (Visit 6, Week 4) to End of Treatment (Visit 25, Month 24))
- Total kidney volume (TKV) annual mean percent change rate [%/year](from baseline to End of Treatment (Visit 25, Month 24))
- eGFR CKD-EPI annual mean change [mL/min/1.73m^2] (off-treatment)(from baseline to the Follow-up visit (Visit 26, 7 days after End of Treatment(Visit 25, Month 24)))
研究者
研究点 (18)
Loading locations...
相似试验
已完成
3 期
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)Autosomal Dominant Polycystic Kidney Disease (ADPKD)NCT02964273Otsuka Pharmaceutical Development & Commercialization, Inc.91
已完成
3 期
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney DiseaseChronic Kidney DiseaseAutosomal Dominant Polycystic Kidney DiseaseNCT02160145Otsuka Pharmaceutical Development & Commercialization, Inc.1,370
已完成
3 期
A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADHSyndrome of Inappropriate Antidiuretic Hormone SecretionNCT03048747Otsuka Pharmaceutical Co., Ltd.16
招募中
不适用
A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.ephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor geneJPRN-UMIN000021708Department of Nephrology and Endocrinology, The University of Tokyo Hospital3
已完成
4 期
The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves ReplacementRight Heart FailureTricuspid RegurgitationNCT02644616Shanghai Chest Hospital40